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Background: Complementary and alternative medicine (CAM) has been used frequently, and its use continues to 
increase in lung cancer patients, despite insufficient scientific of its efficacy. To investigate this situation, we analyzed the 
current awareness and use of CAM in Korean lung-cancer patients.
Methods: This prospective survey–based study was performed at seven medical centers in South Korea between August 
and October 2019. The survey assessed general patient characteristics and the awareness and use of CAM. We analyzed 
differences in the clinical parameters of patients aware and not aware of CAM and of CAM non-users and users.
Results: Of the 434 patients included in this study, 68.8% responded that they were aware of CAM and 30.9% said they 
had experienced it. In univariate analysis, the patients aware of CAM were younger with poor performance status, had 
advanced-stage lung cancer, received more systemic therapy, and received concurrent chemoradiation therapy (CCRT). 
By multiple logistic regression, younger age, poor performance status, advanced stage, and prior CCRT were identified 
as independent risk factors for CAM awareness. There were no significant differences in the general characteristics and 
cancer-associated clinical parameters of CAM non-users and users. 
Conclusion: Specific clinical parameters were associated with patients’ awareness of CAM, although there were no 
significantly different characteristics between CAM users and non-users. 
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Introduction
Lung cancer is the most common cancer and responsible 
for the highest cancer-related mortality worldwide1-4. Although 
the age-adjusted incidence and cancer-related mortality of 
lung cancer have decreased in previous decades, the treat-
ment of lung cancer is still a challenging issue that devastates 
both clinicians and patients5. Regarding these circumstances, 
some patients choose to use therapies that are not scientifi-
cally proven or based on insufficient evidence. These thera-
pies are used either as supplementary/additive measures 
(complementary medicine) or alternative measures (alterna-
tive medicine) to conventional cancer treatment. Such thera-
pies are usually referred to as complementary and alternative 
medicine (CAM)6,7.
The motivations for using CAM are diverse. Patients expect 
to gain a better general condition, improve their immune 
system, relieve cancer symptoms or treatment side effects, 
and prolong survival6,8. However, the results of previous stud-
ies on the efficacy and safety of CAM vary from beneficial to 
harmful6,7,9-13. Thus, a thorough understanding of these results 
by both patients and clinicians is needed before starting treat-
ment with CAM. Nonetheless, previous studies have shown 
that many patients choose to use CAM regardless of the sci-
entific basis, relying more on media or non-specialists than 
physicians, which may be biased by secondary gain, personal 
subjective experience, or unproven information8. As CAM is 
now frequently used worldwide in cancer patients and its use 
continues to increase, its effects on cancer patients should not 
be overlooked14-16. Therefore, it may be important to analyze 
the current status of CAM awareness and the use of CAM to 
guide patients in choosing their treatment.
In this study, we conducted a multicenter survey-based 
study to investigate the current status of CAM awareness and 
use in lung cancer patients, and analyzed the factors associ-
ated with the awareness and use of CAM. Furthermore, we in-
vestigated the adverse events, costs, and perspectives toward 
CAM in CAM users.
Materials and Methods
1.Study design and data collection
This study was a prospective survey-based study performed 
in seven medical centers in South Korea. The patients en-
rolled in this study had pathologically confirmed lung cancer 
and replied to questionnaires in a survey on CAM use be-
tween August 2019 and October 2019 (Supplementary Mate-
rial). The survey consisted of two sections. The first section 
was composed of 13 questions on patient demographics and 
information associated with the patient’s disease (i.e., lung 
cancer staging and treatment), which was attained by the 
attending physicians. The second section was composed of 
15 questionnaires regarding the awareness and use of CAM, 
which was self-reported by the patient in the outpatient clinic.
2. General characteristics and awareness of CAM use 
The patients enrolled in this study were provided with a 
paper survey on personal CAM awareness and use. The ques-
tionnaires consisted of general characteristics such as age, sex, 
Eastern Cooperative Oncology Group (ECOG) performance 
status, smoking history (ever or never smoker), and economic 
status (low vs. medium vs. high). We also gathered informa-
tion associated with the patient’s disease, including lung 
cancer staging (TNM staging in non-small cell lung cancer 
[NSCLC], or limited/extended staging in small cell lung cancer 
[SCLC]), past treatment history (e.g., surgery, radiation thera-
py, systemic therapy or concurrent chemoradiation therapy 
[CCRT]), candidates for targeted therapy (epidermal growth 
factor receptor [EGFR]/anaplastic lymphoma kinase [ALK] 
mutation), line of systemic therapy, and treatment durations. 
We analyzed the differences in these factors in patients aware 
and not aware of CAM and in CAM users and non-users. The 
general patient characteristics were also compared with a pre-
vious unbiased Korean nationwide study that extracted data 
from the Korean Association of Lung Cancer Registry (KALC-
R) in 2014 to investigate whether the enrolled patients repre-
sented the general cancer population of Korea17.
3. Awareness of CAM
The survey included questions on CAM awareness. The 
questionnaires of the awareness of CAM were answered in 
one of the three: “never heard”, “heard only a little” or “known 
thoroughly”. The patients were questioned about their famil-
iarity with procedures or techniques of CAM, such as onco-
thermia, high-dose vitamin C, mistletoe, selenium, Gerson 
therapy, bio-photon, thymosin alpha 1, nebulized oriental 
medicine, acupuncture or moxibustion, oriental medicine, 
mushrooms, ginseng, or reiki treatments. Furthermore, the 
questionnaire included questions on the route through which 
CAM information was obtained, the patient’s expectation of 
efficacy, and whether CAM was based on scientific evidence.
4. Current status of CAM use
In patients who were aware of CAM, they were asked 
whether they had received any CAM procedure or medicine. 
The patients who selected ‘yes’ to that question were asked 
what specific types of CAM they experienced, when they re-
ceived CAM (before, during, or after conventional therapy), 
the duration of CAM use, and their economic status. Also, the 
questionnaires asked about adverse events and the cost of us-
ing CAM.
Current status of alternative medicine
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5. Statistical analysis
All statistical analyses were performed with R software (ver-
sion 3.5.2, R Development Core Team, Vienna, Austria). The 
quantitative variables are presented as mean±standard devia-
tions, and the categorical variables are shown as numbers 
and percentages. The quantitative variables were assessed be-
tween the two groups with a student’s t test and the categorical 
variables were compared with the chi-square test or Fisher ex-
act test. A p-value of less than 0.05 was considered statistically 
significant. 
We performed multiple logistic regression to reveal the 
relationship between CAM awareness and potential associ-
ated factors. First, we performed univariate logistic regression 
Table 1. Patient characteristics and comparison with 






Male sex 308 (71.0) 1,876 (71.6)
Age, yr 66 (60–74) 70 (61–76)
Performance status (ECOG)
   0–1 382 (91.4) 1,756 (93.8)
   2–4 36 (8.6) 117 (6.2)
Smoking history
   Ever smoker 288 (66.4) 1,641 (63.6)
   Never smoker 146 (33.6) 980 (36.4)
Stage
   NSCLC 384 (88.5) 2,265 (86.4)
      I–II 127 (33.0) 824 (36.9)
      III–IV 257 (66.9) 1,410 (63.1)
   SCLC 50 (11.5) 356 (13.6)
      Limited 27 (52.9) 128 (36.6)
      Extended 24 (47.1) 222 (63.4)
Treatments*
   Surgery 167 (40.8) 861 (33.0)
   Systemic therapy 225 (54.9) 870 (33.3)
      Cytotoxic 157 (38.4) -
      Immunotherapy 59 (14.4) -
      Targeted therapy 71 (17.3) -
   Chemoradiation 117 (28.5) 151 (5.8)
   Radiation therapy 79 (19.3) 205 (7.8)
Values are presented as number (%), mean±SD, or median (IQR).
*Patients may have received more than two treatment modalities.
KALC-R: Korean Association of Lung Cancer Registry; ECOG: 
Eastern Cooperative Oncology Group; NSCLC: non-small cell lung 
cancer; SCLC: small-cell lung cancer; SD: standard deviation; IQR: 
interquartile range.











   Male 97 (71.9) 210 (70.5)
   Female 38 (28.1) 88 (29.5)
Age, yr
   ≥65 86 (63.7) 155 (52.0) 0.03
   <65 49 (36.3) 143 (48.0)
Performance status <0.01
   ECOG 0 68 (53.5) 111 (38.3)
   ECOG 1–4 59 (46.5) 179 (61.7)
Pathology 0.98
   NSCLC 120 (88.9) 263 (88.3)
   SCLC 15 (11.1) 35 (11.7)
Stage
   NSCLC I 44 (36.7) 41 (15.6) <0.01
   NSCLC II–IV 76 (63.3) 222 (84.4)
   SCLC limited 7 (46.7) 20 (55.6) 0.79
   SCLC extended 8 (53.3) 16 (44.4)
Treatments*
   Surgery 58 (46.0) 108 (38.3) 0.17
   Systemic therapy 59 (46.8) 165 (58.3) 0.04
   Chemoradiation 20 (15.9) 97 (34.3) <0.01
   Radiation therapy 18 (14.3) 60 (21.3) 0.13
EGFR/ALK (+) 34 (27.4) 75 (26.0) 0.87
Line of systemic therapy 0.46
   1 37 (44.0) 73 (38.4)
   ≥2 47 (56.0) 117 (61.6)
Treatment duration, yr 0.72
   ≥1 69 (51.9) 159 (54.3)
   <1 64 (48.1) 134 (45.7)
Economic status >0.99
   Low 2 (28.6) 26 (26.3)
   Medium-to-high 5 (71.4) 73 (73.7)
Values are presented as number (%).
*Patients may have received more than two treatment modalities.
CAM: Complementary and alternative medicine; ECOG: Eastern 
Cooperative Oncology Group; NSCLC: non-small cell lung cancer; 
SCLC: small cell lung cancer; EGFR: epidermal-growth-factor re-
ceptor; ALK: anaplastic lymphoma kinase.
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Proven sufficiently
Proven by some evidence
Not proven to be scientific
Don t know
Effective in many patients































Figure 1. Patient awareness of complementary and alternative medicine (CAM): (A) proportion of patients aware of CAM, (B) route of acqui-
sition of information on CAM, (C) patient awareness that CAM is effective, and (D) patient awareness of CAM as scientifically proven. 
Table 3. Multiple logistic regression of factors associated with CAM awareness
Variable
Univariate analysis Multivariate analysis
OR (95% CI) p-value OR (95% CI) p-value
Age, yr
   <65 1.62 (1.07–2.46) 0.02 2.09 (1.24–3.53) <0.01
   ≥65 Reference Reference
Performance status
   ECOG 1–4 1.86 (1.22–2.83) <0.01 2.03 (1.20–3.44) <0.01
   ECOG 0 Reference Reference
NSCLC
   Stage II–IV 3.13 (1.90–5.16) <0.01 1.96 (1.01–3.79) 0.046
   Stage I Reference Reference
Systemic therapy
   (+) 1.59 (1.04–2.42) 0.03 1.22 (0.69–2.17) 0.49
   (–) Reference Reference
Chemoradiation
   (+) 2.76 (1.62–4.73) <0.01 2.07 (1.05–4.06) 0.04
   (–) Reference Reference
Hosmer Lemeshow goodness of fit, p=0.61.
CAM: complementary and alternative medicine; OR: odds ratio; CI: confidence interval; ECOG: Eastern Cooperative Oncology Group; 
NSCLC: non-small cell lung cancer.
Current status of alternative medicine
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to select the candidate risk factors for CAM awareness. The 
variables included age (≥65 years vs. <65 years), sex, ECOG 
performance status (0 vs. 1–4), NSCLC staging (I vs. II–IV), 
and past treatment history (surgery, CCRT, systemic therapy, 
radiation therapy). Variables with a p-value of less than 0.05 in 
univariate analysis were selected for multiple logistic regres-
sion analysis. The adjusted odds ratio (OR) of each variable for 
CAM awareness was calculated. 
6. Ethics approval and consent to participate
Ethical approval was obtained from the Ethics Committee 
of Hallym University Sacred Hospital, and the IRB number 
was HALLYM201909001001-HE001. The requirement for in-
formed consent was waived by the Ethics Committee of Hal-
lym University Sacred Hospital.
Results
1. General characteristics
A total of 434 patients were enrolled in this study. The flow 
chart of patients’ enrollment is shown at Supplementary 
Figure S1. The general characteristics and comparison to the 
characteristics of a cancer population in a previous study 
(KALC-R) are shown in Table 117. In this study, 71.0% of the 
patients were male and 91.4% of the patients had an ECOG 
scale score of 0 to 1, which was similar to the KALC-R study. 
The mean patient age in this study was 65.8±9.9 years, which 
was slightly younger than the patients in the KALC-R study. 
The proportion of ever smokers was similar between the two 
studies (66.4% in the current study vs. 63.6% in the KALC-
R study). In the analysis of cancer stages, the proportion of 
NSCLC patients was similar between the two studies. How-
ever, our study showed more limited-stage SCLC patients 
than the KALC-R study (52.9% vs. 36.6%, respectively). Our 
study population received more treatment by all modalities 
compared with the KALC-R study (surgery, 40.8% vs. 33.0%; 
systemic therapy, 54.9% vs 33.3%; CCRT, 28.5% vs. 5.8%; radio-
therapy, 19.3% vs. 7.8%, respectively).
2. Awareness of CAM
We analyzed the differences in the characteristics and clini-
cal parameters between patients aware of CAM and those 
not aware of CAM (Table 2). A total of 68.8% of patients were 
aware of CAM. Those aware of CAM were younger patients 
with poorer performance status. Among the NSCLC patients, 
patients aware of CAM had less stage I disease (15.6% vs. 
36.7%, respectively, p<0.01), but there was no significant differ-
ence in the cancer stage of the SCLC patients. Patients aware 
of CAM received more systemic therapy (58.3% vs. 46.8%, 











   Male 144 (71.6) 60 (66.7)
   Female 57 (28.4) 30 (33.3)
Age, yr 0.16
   ≥65 111 (55.2) 41 (45.6)
   <65 90 (44.8) 49 (54.4)
Performance status 0.47
   ECOG 0 79 (40.1) 31 (34.8)
   ECOG 1–4 118 (59.9) 58 (65.2)
Pathology 0.90
   NSCLC 176 (87.6) 80 (88.9)
   SCLC 25 (12.4) 10 (11.1)
Stage
   NSCLC I 28 (15.9) 11 (13.8) 0.80
   NSCLC II–IV 148 (84.1) 69 (86.2)
   SCLC limited 16 (64.0) 4 (36.4) 0.24
   SCLC extended 9 (36.0) 7 (63.6)
Treatments*
   Surgery 70 (37.4) 36 (40.9) 0.68
   Systemic therapy 113 (60.1) 48 (54.5) 0.46
   Chemoradiation 64 (34.0) 32 (36.4) 0.81
   Radiation therapy 39 (20.7) 18 (20.7) >0.99
EGFR/ALK (+) 51 (26.2) 22 (25.6) >0.99
Line of systemic therapy 0.15
   1 57 (42.2) 15 (29.4)
   ≥2 78 (57.8) 36 (70.6)
Treatment duration, yr 0.04
   ≥1 97 (49.2) 56 (62.9)
   <1 100 (50.8) 33 (37.1)
Economic status 0.12
   Low 6 (50.0) 20 (23.8)
   Medium-to-high 6 (50.0) 64 (76.2)
Values are presented as number (%).
*Patients may have received more than two treatment modalities.
CAM: complementary and alternative medicine; ECOG: Eastern 
Cooperative Oncology Group; NSCLC: non-small cell lung cancer; 
SCLC: small cell lung cancer; EGFR: epidermal-growth-factor re-
ceptor; ALK: anaplastic lymphoma kinase.
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respectively, p=0.04) and CCRT (34.3% vs. 15.9%, respectively, 
p<0.01). However, there was no statistical difference in previ-
ous surgery or radiotherapy between the two groups. Further-
more, there was no statistical difference in sex, pathology type 
(NSCLC/SCLC), EGFR positivity or ALK mutations, the line of 
systemic therapy (1 vs. ≥2), treatment duration (≥1 year vs. <1 
year), or economic status of the patients (low vs. medium-to-
high).
In this study, 6.9% of the patients responded that they were 
thoroughly aware of CAM and 31.1% of the patients answered 
that they never heard of it (Figure 1A). The most commonly 
known CAM treatments were mushrooms, oncothermia, 
high-dose vitamin C, and ginseng (Supplementary Figure S2). 
The most common route for obtaining information on CAM 
was through friends or acquaintances and by the internet or 
visiting stores (Figure 1B). Around one-third of the patients 
replied that CAM may be effective or was proven by scientific 
evidence, and the remainder regarded CAM as not effective, 
not proven scientifically, or did not know (Figure 1C, D). 
Univariate analysis of CAM awareness with potential asso-
ciated factors showed statistical significance with age (p=0.02), 
performance status (p<0.01), cancer staging in NSCLC 
(p<0.01), previous systemic therapy (p=0.03), and previous 
CCRT (p<0.01). Multiple logistic regression was performed 
with variables that showed significance in univariate analysis 
(Table 3). In this regression model, younger patients (OR, 
2.09; p<0.01), poorer performance status (OR, 2.03; p<0.01), 
advanced stage in NSCLC (OR, 1.96; p=0.046), and previous 
CCRT (OR, 2.07; p=0.04) were associated with CAM aware-
ness. The Hosmer Lemeshow goodness of fit had a calculated 
p-value of 0.61.
3. Usage of CAM
We investigated the differences in the characteristics and 
clinical parameters between CAM users and non-users (Table 
4). CAM users comprised 30.9% of our study population. 
CAM users had a tendency to be younger (54.4% vs. 44.8%, re-
spectively, p=0.16), more likely to be female (33.3% vs. 28.4%, 
respectively, p=0.47), and in advanced stages in the NSCLC 
patients (86.2% vs. 84.1%, respectively, p=0.80), but the find-
ings did not meet statistical significance. Also, there were no 
statistical differences in performance status, pathology, treat-
ments, or economic status between the two groups. The only 
statistically significant factor was treatment duration of more 
than 1 year, which was more common in the CAM user group 
compared to the non-user group (62.9% vs. 49.2%, respective-
ly, p=0.04). However, no significantly different factors between 
the CAM users and non-users were found in multivariate 
analysis. The most frequently used CAM was mushrooms, on-
cothermia, ginseng, and high-dose vitamin C (Supplementary 
Figure S3) and most of the CAM users received CAM during 
conventional treatment (Figure 2A). The duration of CAM 
treatment was not significantly different (Figure 2B), and 
74.0% of the patients were in the medium-to-high economic 
group (Figure 2C). A total of 24.2% of the patients experienced 
adverse events from CAM, mostly pruritus or rash, fatigue, and 
insomnia (Supplementary Figure S4). Almost half of the pa-
tients paid less than 1,000 USD and 21.1% of the patients paid 
over 5,000 USD for CAM (Supplementary Figure S5). Finally, 
only 18.9% of the CAM users were willing to recommend 
CAM to other patients and 45.3% of the patients were against 
recommending it (Supplementary Figure S6).
Discussion
In this study, we analyzed the awareness and usage of CAM 
in a multicenter survey-based lung cancer population. In 


















































































Figure 2. Timing (A) and duration (B) of complementary and alternative medicine (CAM) use, and economic status (C) of the CAM users.
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aware of CAM and more CAM users were younger patients 
with poor performance status, advanced stage in NSCLC 
patients, and those who received systemic therapy or CCRT. 
In multivariate analysis, young age, poor performance status, 
advanced stage in NSCLC patients, and previous CCRT were 
independent factors associated with CAM awareness. In con-
trast, there were no statistically significant variables that dif-
fered between the CAM users and non-users. 
The proportion of cancer patients who experienced CAM 
was shown to be 30.9% in our study, and was reported to vary 
between 11% and 90% in previous studies18-20. Previous stud-
ies showed some distinct characteristics of CAM users com-
pared to non-users. CAM users were usually younger; consist-
ed of more female, educated, and white-collar patients; lived 
in highly urban areas; had advanced-stage cancer; were less 
physically active, and received psychological support8,14,21,22. 
Also, those who were interested in CAM or used CAM previ-
ously chose to use CAM more frequently8. Correspondingly, 
our study found that the CAM users were younger, more likely 
to be female, and at an advanced stage, but these findings did 
not reach statistical significance. 
To our knowledge, no previous studies analyzed the factors 
associated with CAM awareness. However, it may be postulat-
ed that patients aware of CAM and CAM users share similar 
characteristics. Our study showed that patients aware of CAM 
were more likely to be younger, have poor performance status, 
and advanced stage in NSCLC patients, which corresponded 
to the characteristics of CAM users reported in the previous 
study mentioned above. Also, between treatment modalities, 
only CCRT was an independent risk factor for CAM aware-
ness. Patients with unresectable stable III NSCLC or limited 
SCLC disease receiving CCRT may have higher potential 
for cure but higher treatment-associated toxicity than more 
advanced patients receiving palliative chemotherapy, which 
may result in a higher awareness of CAM23. 
The World Health Organization (WHO) defined CAM as 
“a broad set of healthcare practices that are not part of that 
country’s own tradition or conventional medicine and are not 
fully integrated into the dominant healthcare system24.” Also, 
the organization mentioned that it might be used alternatively 
with traditional medicine. This definition implies that these 
interventions are not fully proven to be effective or safe, nor 
are they based on scientific evidence. Some experimental, 
retrospective studies or small prospective studies have shown 
the potential efficacy or safety of CAM, such as oncother-
mia25,26, high-dose vitamin C25,27, mistletoe11,28,29, thymosin 
alpha 130,31, or oriental medicine10,12,32-34. However, some stud-
ies have shown the harmful effects of CAM, such as treatment 
delay, treatment refusal, and increased mortality7,13,35. At the 
crossroads of choice, clinicians and patients should fully un-
derstand not only the potentially favorable outcomes but also 
the devastating consequences of CAM. However, our data and 
previous studies showed that the source of information about 
CAM was mainly friends and the media8,14. These previous 
studies also reported the lack of doctors’ roles in providing 
information about CAM. This situation may misguide patients 
to have meaningless hope, spend money recklessly, and, most 
seriously, refuse conventional treatment. 
Most of the studies reported that the patients were usually 
satisfied36,37 with little or transient side effects14,38. However, our 
study showed that only 18.9% of the CAM users were satisfied 
and 24.2% experienced side effects from CAM. Considering 
the heterogeneity of each CAM intervention, satisfaction, and 
side effects should be analyzed by the type of CAM adminis-
tered15. 
There were some limitations to this study. First, this study 
was a cross-sectional study based on a survey. As a result, this 
study design may include some bias, such as recall bias or se-
lection bias. Second, as this study population was mainly en-
rolled in a secondary or tertiary hospital, it may not represent 
patients who were receiving conservative or palliative treat-
ment in primary clinic or CAM clinics. Third, as described in 
Table 1, our patients consisted of more of limited-stage SCLC 
and were treated with all types of modalities compared to 
the previous population-based study17. We contend that the 
expanded concept of lung cancer screening may have re-
sulted in increased numbers of lung cancer patients detected 
at earlier stages or with treatable disease39. Also, drastic im-
provements in treatments such as immunotherapy in the last 
decade may have increased the number of patients indicated 
for treatment40. Furthermore, as our survey was performed 
in outpatient clinics of secondary or tertiary hospitals, the 
patients enrolled in our study may have been more frequently 
followed-up and adhered to treatment.
Despite these limitations, there were some strengths to 
our study. First, to our knowledge, this was the first study to 
analyze factors associated with the awareness of CAM. We 
performed multivariate analysis to reveal the independent 
risk factors for patients aware of CAM. Also, we compared the 
variables that potentially differed between CAM users and 
non-users. Although there were no differences between the 
two groups, this was the first study that compared not only 
general characteristics such as age, sex, and economic status, 
but also the detailed variables associated with diagnosis and 
treatment, including pathology type, cancer staging, treatment 
modalities, EGFR /ALK mutation, and the line of systemic 
therapy. These factors were correspondingly analyzed be-
tween patients aware and not aware of CAM, which were not 
evaluated in previous studies.
In conclusion, we analyzed the differences in characteristics 
between patients aware of CAM and those not aware. By mul-
tivariate analysis, we concluded that patients with younger 
age, poor performance status, advanced stage, and those who 
received prior CCRT were more aware of CAM. They obtained 
information on CAM mostly from friends and acquaintances, 
and one-third of the patients responded that they believed 
JY Choi et al.
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CAM was effective or scientifically proven. There were no 
significantly different characteristics between CAM users and 
non-users.
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